Trulieve Reports Second Quarter 2026 Results
Bullish on TRLV over the next 1–3 quarters as expansion, buyback, and NYSE listing drive upside.
Signal detail
Source-backed analysis, the reasoning behind the signal, and its market context.
Bullish on TRLV over the next 1–3 quarters as expansion, buyback, and NYSE listing drive upside.
What happened and why it matters
Trulieve reported Q2 2026 revenue of $271 million with a 60% gross margin, underscoring strong retail demand. GAAP net loss of $406 million reflects Harvest deconsolidation, while adjusted metrics show $20 million of net income and $98 million of EBITDA. The NYSE listing (TRLV) and a $50 million share repurchase bolster liquidity ahead of Georgia expansion and further markets.
The stock benefits from a clearer U.S. listing (NYSE), a tangible capital return via buyback, and expansion progress in Georgia, all of which can support better liquidity, improved multiples, and faster capital redeployment. The Harvest deconsolidation is a one-time hit on GAAP earnings, but non-GAAP metrics show solid cash-generation, suggesting improved underlying value.
Q2 revenue $271M; gross margin 60%; GAAP bottom line hit by Harvest deconsolidation.
Harvest deconsolidation caused $406M GAAP net loss; adjusted net income $20M.
NYSE listing achieved; ticker TRLV; share buyback up to $50M.
Georgia shipments to licensed pharmacies; Florida dispensaries opened (4).
Management sees expansion tailwinds; non-GAAP metrics highlight underlying cash generation.
Trulieve earnings release fits Earnings with accompanying Corporate Developments; it combines GAAP and Non-GAAP measures, highlights one-time Harvest effects, and emphasizes growth catalysts (Georgia expansion, buyback, NYSE listing). This framing supports a near-term price focus on liquidity, multiple expansion, and cash generation rather than GAAP net income alone.
More AI-analyzed coverage connected to this story